Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

UWE Bristol signs up for latest version of simulated Eclipse Radiotherapy Treatment Planning System

The University of the West of England (UWE Bristol) is the first Higher Education Institution (HEI) in the UK to sign up for the very latest version of a powerful simulated Radiotherapy Treatment Planning System (RTPS), which has been futureproofed.

14 Aug 2015

New data assesses actionability of multigene panel testing for hereditary breast and ovarian cancer risk

Multigene testing of women negative for BRCA1 and BRCA2 found some of them harbored other harmful genetic mutations, most commonly moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase ovarian cancer risk, according to an article published online by JAMA Oncology.

14 Aug 2015

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

14 Aug 2015

Combination of chemotherapy and immune-blocking drug could prevent cancer recurrence

Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people, according to research published today in Cancer Research.

13 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

CrystalGenomics, Inc. has announced that it has signed a Sales and Marketing Agreement with Dong-A ST Co., Ltd. for the commercialization of Acelex (polmacoxib) in Korea.

13 Aug 2015

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.

12 Aug 2015

Amyloid-beta kinetics reveal link between aging and AD risk

Slowed amyloid-beta turnover may explain aging’s association with increased amyloidosis and Alzheimer’s disease, say researchers.

12 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

Concord Medical closes acquisition of additional ownership interest in MD Anderson Proton Therapy Center

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has closed the acquisition of additional ownership interest of The University of Texas MD Anderson Cancer Center Proton Therapy Center ("MD Anderson Proton Therapy Center").

12 Aug 2015

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Biomarkers are an important part in detecting certain cancers such as the BRCA gene in breast cancer and the PSA antigen in prostate cancer. They are easy to identify in a blood test and can help in diagnosing and giving a prognosis.

12 Aug 2015

JAYAO article highlights benefits and risks of adolescent sibling stem cell donation

A sibling may often be the best match for a patient who needs a stem cell transplant, but especially for adolescent donors, who are at a vulnerable age, factors such as the responsibility to donate versus a perception of free choice and the potential for anxiety and guilt in the face of complications or poor outcomes demand careful consideration.

12 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice.

12 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.

11 Aug 2015

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Aeterna Zentaris Inc. today announced that the independent Data and Safety Monitoring Board for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.

11 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead academic centers participating in the National Cancer Institute's (NCI) MATCH (Molecular Analysis for Therapy Choice) Trial in the United States, set to begin in the next few weeks.

11 Aug 2015

Oncology News and Research

Further Reading

UWE Bristol signs up for latest version of simulated Eclipse Radiotherapy Treatment Planning System

New data assesses actionability of multigene panel testing for hereditary breast and ovarian cancer risk

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Combination of chemotherapy and immune-blocking drug could prevent cancer recurrence

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

Amyloid-beta kinetics reveal link between aging and AD risk

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Concord Medical closes acquisition of additional ownership interest in MD Anderson Proton Therapy Center

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

JAYAO article highlights benefits and risks of adolescent sibling stem cell donation

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Cost of radiation therapy varies widely among Medicare patients with cancer

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News